Preview | Agreement |

Document Preview

Agreement

Click "Add to Cart" button to purchase document.
Documents are emailed immediately after purchase.
You can also browse documents by title, category, or company... or click here for help finding documents.

Title:

Agreement

Entities:

Avigen, Inc.; Bayer AG; Stanford University

Date:

2001

Size:

Preview shows 5KB of 265KB total

Price:

$70

ID:

#286847

► Miscellany ► Agreements
► Biotechnology & Drugs
► Miscellany ► Universities
► Biotech & Drugs ► In Vitro & In Vivo Diagnostic Substances

Start of Preview

                                    AGREEMENT





                                     BETWEEN





                                  AVIGEN, INC.





                                       AND



                                BAYER CORPORATION



















                                       1

{PAGE}   2



                                TABLE OF CONTENTS



{TABLE}

{CAPTION}

                                                                             PAGE



{S}          {C}                                                             {C}

ARTICLE 1.      DEFINITIONS .................................................  2



    1.1      "AAV" ..........................................................  2



    1.2      "AAV-FIX" ......................................................  2



    1.3      "AE" ...........................................................  2



    1.4      "Affiliate" ....................................................  2



    1.5      "Agreement" ....................................................  2



    1.6      "Avigen Core Technology" .......................................  2



    1.7      "Avigen Core Technology Rights" ................................  3



    1.8      "Avigen Improvement Rights" ....................................  3



    1.9      "Avigen Improvements" ..........................................  3



    1.10     "Avigen Indemnitee" ............................................  3



    1.11     "Avigen Know-How" ..............................................  3



    1.12     "Avigen Trademark" .............................................  3



    1.13     "Bayer Improvement Rights" .....................................  3



    1.14     "Bayer Improvements" ...........................................  3



    1.15     "Bayer Indemnitee" .............................................  3



    1.16     "Bayer Know-How" ...............................................  3



    1.17     "Bayer Trademark" ..............................................  4



    1.18     "BLA" ..........................................................  4



    1.19     "Business Day" .................................................  4



    1.20     "Certificate of Analysis" ......................................  4



    1.21     "Claim" ........................................................  4



    1.22     "Clinical Development" .........................................  4



    1.23     "Commercial Launch" ............................................  5



    1.24     "Commercialize" ................................................  5



    1.25     "Commercially Reasonable Efforts" ..............................  5



    1.26     "Competing Product" ............................................  5



    1.27     "Competitor" ...................................................  5



    1.28     "Confidential Information" .....................................  5



    1.29     "Damages" ......................................................  5

{/TABLE}



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY

BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE

COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS

AMENDED.







                                       i

{PAGE}   3



                                TABLE OF CONTENTS

                                   (CONTINUED)



{TABLE}

{CAPTION}

                                                                             PAGE



{S}          {C}                                                             {C}

    1.30     "Dollar" ......................................................   5



    1.31     "Dominated" ...................................................   5



    1.32     "Dose" ........................................................   5



    1.33     "Effective Date" ..............................................   5



    1.34     "EMEA" ........................................................   5



    1.35     "Existing Licenses" ...........................................   5



    1.36     "Facility" ....................................................   6

End of Preview

Home Intelligence Services Subscriptions News About Us